A six-year clinical study of therapy of cardiomyopathy with coenzyme Q10.
One hundred and forty-three cases of chronic, stable, non-secondary, non-hypertrophic cardiomyopathy, 98% of whom were in NYHA Classes III and IV, were given 100 mg of coenzyme Q10 orally in addition to their conventional medical programme in an open-label long-term study. Blood CoQ10 levels, clinical status, myocardial function and survival have been recorded now for almost 6 years. Mean control/CoQ10 levels of 0.85 micrograms/ml rose to 2 micrograms/ml in 3 months and remained stable at that level. Mean ejection fraction of 44% measured by systolic time interval analysis rose to 60% within 6 months and stabilized at that level with 84% of patients showing statistically significant improvement. Eighty-five percent of patients improved by one or two NYHA Classes. Survival figures were encouraging with an 11.1% mortality in 12 months and 17.8% mortality in 24 months, comparing favourably with several reports in the literature. There was no positive evidence of toxicity or intolerance in a total of 368.9 patient-years of exposure. Coenzyme Q10 is safe and effective long-term therapy for chronic cardiomyopathy.
Langsjoen
P H
PH
Department of Medicine, Scott & White Clinic, Temple, TX.
Langsjoen
P H
PH
Folkers
K
K
D000328:Adult; D000368:Aged; D009202:Cardiomyopathies / Q000188:drug therapy* / Q000401:mortality; D003067:Coenzymes; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D013318:Stroke Volume / Q000187:drug effects; D015996:Survival Rate; D014451:Ubiquinone / Q000627:therapeutic use* / Q000031:analogs & derivatives
D003067:Coenzymes; D014451:Ubiquinone; C024989:coenzyme Q10